De Novo Mutations Affecting the Catalytic Cα Subunit of PP2A, PPP2CA, Cause Syndromic Intellectual Disability Resembling Other PP2A-Related Neurodevelopmental Disorders.
PP2A
PP2A-related neurodevelopmental disorders
PPP2CA
de novo mutation
epilepsy
intellectual disability
syndrome
Journal
American journal of human genetics
ISSN: 1537-6605
Titre abrégé: Am J Hum Genet
Pays: United States
ID NLM: 0370475
Informations de publication
Date de publication:
03 01 2019
03 01 2019
Historique:
received:
06
06
2018
accepted:
06
12
2018
pubmed:
1
1
2019
medline:
5
11
2019
entrez:
1
1
2019
Statut:
ppublish
Résumé
Type 2A protein phosphatases (PP2As) are highly expressed in the brain and regulate neuronal signaling by catalyzing phospho-Ser/Thr dephosphorylations in diverse substrates. PP2A holoenzymes comprise catalytic C-, scaffolding A-, and regulatory B-type subunits, which determine substrate specificity and physiological function. Interestingly, de novo mutations in genes encoding A- and B-type subunits have recently been implicated in intellectual disability (ID) and developmental delay (DD). We now report 16 individuals with mild to profound ID and DD and a de novo mutation in PPP2CA, encoding the catalytic Cα subunit. Other frequently observed features were severe language delay (71%), hypotonia (69%), epilepsy (63%), and brain abnormalities such as ventriculomegaly and a small corpus callosum (67%). Behavioral problems, including autism spectrum disorders, were reported in 47% of individuals, and three individuals had a congenital heart defect. PPP2CA de novo mutations included a partial gene deletion, a frameshift, three nonsense mutations, a single amino acid duplication, a recurrent mutation, and eight non-recurrent missense mutations. Functional studies showed complete PP2A dysfunction in four individuals with seemingly milder ID, hinting at haploinsufficiency. Ten other individuals showed mutation-specific biochemical distortions, including poor expression, altered binding to the A subunit and specific B-type subunits, and impaired phosphatase activity and C-terminal methylation. Four were suspected to have a dominant-negative mechanism, which correlated with severe ID. Two missense variants affecting the same residue largely behaved as wild-type in our functional assays. Overall, we found that pathogenic PPP2CA variants impair PP2A-B56(δ) functionality, suggesting that PP2A-related neurodevelopmental disorders constitute functionally converging ID syndromes.
Identifiants
pubmed: 30595372
pii: S0002-9297(18)30453-1
doi: 10.1016/j.ajhg.2018.12.002
pmc: PMC6323609
pii:
doi:
Substances chimiques
Protein Subunits
0
PPP2CA protein, human
EC 3.1.3.16
Protein Phosphatase 2
EC 3.1.3.16
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
139-156Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2018 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.
Références
J Biol Chem. 2012 Feb 10;287(7):4853-62
pubmed: 22167190
Nat Cell Biol. 2010 Sep;12(9):886-93
pubmed: 20711181
Mol Cell. 2016 Aug 18;63(4):686-695
pubmed: 27453045
Am J Physiol Heart Circ Physiol. 2000 Sep;279(3):H1307-18
pubmed: 10993798
Nat Commun. 2017 Dec 22;8(1):2272
pubmed: 29273778
Cell. 2006 Oct 20;127(2):341-53
pubmed: 17055435
Nature. 2014 Jul 17;511(7509):344-7
pubmed: 24896178
Nature. 2017 Feb 23;542(7642):433-438
pubmed: 28135719
Biochem J. 2001 Feb 1;353(Pt 3):417-39
pubmed: 11171037
J Clin Invest. 2015 Aug 3;125(8):3051-62
pubmed: 26168268
J Biol Chem. 1993 Sep 15;268(26):19192-5
pubmed: 8396127
Eur J Med Genet. 2010 Sep-Oct;53(5):239-43
pubmed: 20601260
Epilepsy Res. 2017 Mar;131:1-8
pubmed: 28199897
Nat Genet. 2001 Nov;29(3):287-94
pubmed: 11685209
Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):6043-7
pubmed: 8650216
FEBS J. 2013 Jan;280(2):644-61
pubmed: 22443683
Hum Mol Genet. 2015 Sep 1;24(17):4775-9
pubmed: 25972378
Trends Biochem Sci. 2008 Mar;33(3):113-21
pubmed: 18291659
Mol Cell. 2011 Feb 4;41(3):331-42
pubmed: 21292165
Nat Rev Genet. 2016 Jan;17(1):9-18
pubmed: 26503795
Biochem Biophys Res Commun. 2017 Dec 16;494(3-4):491-498
pubmed: 29066346
J Biol Chem. 1999 May 14;274(20):14382-91
pubmed: 10318862
Am J Hum Genet. 2016 Jan 7;98(1):58-74
pubmed: 26749308
Nature. 2015 Mar 12;519(7542):223-8
pubmed: 25533962
J Biol Chem. 1999 Aug 20;274(34):24038-46
pubmed: 10446173
N Engl J Med. 2012 Nov 15;367(20):1921-9
pubmed: 23033978
Am J Med Genet A. 2008 May 15;146A(10):1267-79
pubmed: 18412109
Nat Commun. 2013;4:2677
pubmed: 24157919
Nat Methods. 2014 Apr;11(4):361-2
pubmed: 24681721
Mol Cell Biol. 2011 Sep;31(18):3832-44
pubmed: 21791616
Hum Mutat. 2015 Oct;36(10):928-30
pubmed: 26220891
Cell Res. 2014 Feb;24(2):190-203
pubmed: 24100351
PLoS Genet. 2016 May 11;12(5):e1006022
pubmed: 27166630
Biochemistry. 1999 Dec 14;38(50):16539-47
pubmed: 10600115
Cancer Res. 2016 Oct 1;76(19):5719-5731
pubmed: 27485451
Neurogenetics. 2016 Jan;17(1):43-9
pubmed: 26576547
Dev Dyn. 2014 Jun;243(6):778-90
pubmed: 24425002
Nat Neurosci. 2016 Sep;19(9):1194-6
pubmed: 27479843
Nat Commun. 2013;4:1699
pubmed: 23591866
Cancer Res. 2017 Dec 15;77(24):6825-6837
pubmed: 29046336
J Cell Biol. 2016 Aug 29;214(5):539-54
pubmed: 27551054
Biol Chem. 2014 Jul;395(7-8):881-9
pubmed: 25003389
Am J Med Genet A. 2003 Nov 15;123A(1):37-44
pubmed: 14556245
Lancet. 2012 Nov 10;380(9854):1674-82
pubmed: 23020937
Methods Mol Biol. 2013;1053:283-305
pubmed: 23860660
J Biol Chem. 2007 Sep 14;282(37):26971-80
pubmed: 17635907
Int J Biochem Cell Biol. 2018 Feb;95:53-62
pubmed: 29274472
Cancer Res. 2005 Sep 15;65(18):8183-92
pubmed: 16166293
Biochim Biophys Acta Mol Cell Res. 2019 Jan;1866(1):31-50
pubmed: 30030003